益佰製藥(600594.SH):收到貴州省藥品監督管理局《暫停生產、銷售通知書》
格隆匯8月5日丨益佰製藥(600594.SH)公佈,公司收到貴州省藥品監督管理局出具的《暫停生產、銷售通知書》(黔藥監生產(藥化)暫停[2025]4號),現將相關情況公告如下:
《暫停生產、銷售通知書》的主要內容:在國家藥品監督管理局食品藥品審覈查驗中心開展的檢查工作中,發現你公司存在缺陷,涉及個別記錄企業未如實填寫,部分電子數據未能採用可靠的方式進行記錄。經國家藥監局覈查中心綜合評定,結論爲不符合。根據國家藥監局藥品監管司《關於對貴州益佰製藥股份有限公司有關問題調查處理的通知》(藥監藥管函[2025]277號)要求,結合《貴州省藥品監督管理局藥品安全隱患風險控制措施執行規則》第七條中暫停生產、銷售的情形,按照《藥品檢查管理辦法(試行)》第六十一條之規定,現通知你單位自收到本通知後立即暫停小兒止咳糖漿生產、銷售。
公司產品小兒止咳糖漿2021年、2022年、2023年、2024年的營業收入分別爲342萬元、432萬元、838萬元、151萬元,佔公司當期合併報表營業收入的比例分別爲0.10%、0.16%、0.30%、0.07%,收入佔比較小。本次小兒止咳糖漿暫停生產、銷售預計不會對公司業績產生較大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.